Dudediligence.

Ultragenyx Pharmaceutical Inc

RARENASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$139.5MSep ’24$164.6MDec ’24$139.0MMar ’25$166.5MJun ’25$159.9MSep ’25$207.3MDec ’25$136.0MMar ’26$214.0MJun ’26
Net income, by quarter
−$133.5MSep ’24−$133.2MDec ’24−$151.0MMar ’25−$115.0MJun ’25−$180.4MSep ’25−$128.6MDec ’25−$185.0MMar ’26−$92.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$351.4M$363.3M$434.0M$560.0M$673.0M
Operating income−$381.7M−$648.9M−$569.0M−$536.0M−$535.0M
Net income−$454.0M−$707.4M−$607.0M−$569.0M−$575.0M
Operating cash flow−$338.7M−$380.5M−$475.0M−$414.0M−$466.0M
Free cash flow−$411.8M−$496.6M−$519.0M−$421.0M−$472.0M
Cash$307.6M$132.9M$214.0M$174.0M$421.0M
Shares outstanding69.3M70.2M82.3M92.5M96.6M